|
Abatacept |
|
Hospital use only
|
|
|
Adalimumab syringe |
- TA199 - Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis
- TA195 - Drugs for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor
- TA143 - Adalimumab, etanercept and infliximab for ankylosing spondylitis
- TA130 - Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis
- TA373 - Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
- TA375 - Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
- TA715 - Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed
|
|
|
Allopurinol tablets |
|
|
|
|
Anakinra (Kineret®) |
|
|
|
|
Apremilast (Otezla®) |
|
|
|
Azathioprine#10.1 |
|
Supported by ESCA
|
|
|
Baricitinib (Olumiant®) |
|
Hospital use only
|
|
|
Belimumab |
|
Hospital use only
|
|
|
Belimumab (Benlysta®) |
|
|
|
|
Brodalumab (Kyntheum®) |
|
|
|
|
Celecoxib capsules |
|
RICaD - CVD risk assessment in development
|
|
|
Certolizumab injection |
|
Hospital use only
|
|
|
Ciclosporin |
|
ESCA
|
|
|
Colchicine tablets |
|
|
|
|
Diclofenac sodium dispersible tablets |
|
Very high relative cost. Short term use only. Swallowing difficulties.
|
|
|
Diclofenac sodium E/C tablets |
|
Short term use only
|
|
|
Diclofenac sodium injection |
|
Short term use only
|
|
|
Diclofenac sodium suppositories |
|
Short term use only
|
|
|
Etanercept syringe |
|
|
|
|
Febuxostat tablets |
|
|
|
|
Filgotinib (Jyseleca®) |
|
|
|
|
Golimumab injection |
|
Hospital use only
|
|
|
Hydrocortisone acetate injection |
|
|
|
|
Hydroxychloroquine tablets |
|
|
|
|
Ibuprofen suspension |
|
If swallowing difficulties and paediatric use
|
|
|
Ibuprofen tablets |
|
|
|
|
Indometacin capsules |
|
For gout and resistant case
|
|
|
Indometacin M/R capsules |
|
For gout and resistant case
|
|
|
Indometacin suspension (100ml) |
|
For gout and resistant case
|
|
|
Infliximab injection (Remicade®, Inflectra®, Remsima®) |
- TA199 - Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis
- TA195 - Drugs for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor
- TA143 - Adalimumab, etanercept and infliximab for ankylosing spondylitis
- TA130 - Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis
- TA375 - Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
- TA715 - Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed
|
|
|
|
Ketoprofen injection |
|
|
|
|
Leflunomide tablets |
|
ESCA
|
|
|
Mefenamic acid capsules |
|
For dysmenorrhoea
|
|
|
Mefenamic acid tablets |
|
For dysmenorrhoea
|
|
|
Methotrexate 2.5mg tablets |
|
Supported with an ESCA. Methotrexate tablets - use 2.5mg strength ONLY. Methotrexate injection - Metoject is APC preferred brand. Check cytotoxic disposal arrangements locally.
|
|
|
Methotrexate injections |
|
Supported with an ESCA. Metoject is APC preferred brand. Check cytotoxic disposal arrangements locally.
|
|
|
Methylprednisolone acetate |
|
|
|
|
Methylprednisolone/lidocaine injection |
|
|
|
|
Naproxen tablets |
|
|
|
|
Penecillamine tablets |
|
ESCA
|
|
|
Prednisolone tablets#10.1 |
|
Plain tablets (not enteric coated). Second line in gout.
|
|
|
Probenecid tablets |
|
Hospital use only
|
|
|
Rasburicase injection |
|
|
|
|
Ritumixab infusion (Mabthera®, Truxima®) |
|
|
|
|
Sulfasalazine#10.1 |
|
ESCA
|
|
|
Sulindac tablets |
|
Polyhydramnios (women only)
|
|
|
Tocilizumab (Tyenne® Roactemra®) |
|
Hospital use only
|
|
|
Triamcinolone injection |
|
|
|
|
Upadacitinib (Rinvoq®) |
|
|
|
|
Ustekinumab |
|
Hospital use only
|
